AUTHORS
Kira Li Nagoshi, Meesha Vullikanti, MS2, Valentina Restrepo, M.D.3, Bria Carrithers, M.D., M.S.4, Layla N. Van Doren, MD, MBA5
AFFILIATIONS
1 Yale School of Medicine, New Haven, Connecticut, United States
2 Yale School of Medicine, New Haven, Connecticut, United States
3 Yale New Haven Hospital, New Haven, Connecticut, United States
4 Yale School of Medicine, New Haven, Connecticut, United States
5 University of California, San Francisco, San Francisco, California, United States
ABSTRACT
Background
Pregnant individuals with sickle cell disease (SCD) have increased risk of maternal and perinatal morbidity and mortality, making tailored prenatal care essential. Guidelines from the Society of Maternal-Fetal Medicine (SMFM) recommend a multidisciplinary approach that includes maternal-fetal medicine (MFM), Hematology, Genetics, and subspecialties specific to existing SCD complications that may worsen during pregnancy. Real-world patterns of prenatal care for patients with SCD are not well-characterized.
Methods
We conducted a retrospective-prospective cohort study of SCD pregnancies at an academic tertiary hospital from 2015 to 2025. SCD diagnosis was confirmed via hemoglobin electrophoresis. Each patient’s earliest pregnancy ending in a live birth with sufficient data was included. We collected baseline demographic and clinical characteristics, including obstetric history, SCD genotype & complications, and referrals/visits from initial prenatal visit through delivery. We assessed visits/referrals to Hematology, Genetics, and Reproductive Endocrinology & Infertility (REI) prior to the initial prenatal visit. Descriptive analysis was conducted with the primary outcome of referral to MFM, Genetics, and REI. Secondary outcomes explored care team composition, length of antepartum care, and partner SCD testing outcomes. Significance testing was completed for ordinal variables using Mann-Whitney U.
Results
Cohort Description:
35 patients were included in the analysis. Median (IQR) maternal age at delivery was 28 (24-31.5), with median (IQR) gravidity 2 (1-3) and parity 0 (0-1). 16 patients (46%) had a prior pregnancy loss, and 6/16 (38%) had recurrent pregnancy loss (>1 loss). 16 patients (46%) had genotype HbSS, 12 (34%) HbSC, and 7 (20%) HbSβ+. Median (IQR) pre-pregnancy SCD complications was 1 (0-2), with HbSC patients having the fewest (median 0 vs 2, p < 0.01). 6 patients (17%) initiated prenatal care elsewhere and transferred care to our center mid-pregnancy. Median (IQR) length of prenatal care at our center was 28.7 weeks (26.3-29.4, n=29) for non-transfers and 10.1 weeks (8.1-13.2, n=6) for transfers.
Specialty Utilization:
From initial prenatal visit to delivery, patients were referred to a median (IQR) of 4 (3-5) outpatient specialties related to SCD, with 3 (1.5-3) being new referrals. The most represented were MFM (33/35), Hematology (25/35), Genetics (20/35), Social Work (19/35), Ophthalmology (14/35), and Cardiology/Cardio-Obstetrics (6/35). Of patients with pre-pregnancy retinopathy or proteinuria, 8/13 (62%) and 2/5 (40%) were referred to Ophthalmology or Nephrology during pregnancy.
Hematology, Genetics, and REI were further assessed outside the initial-prenatal-to-delivery window. In total, 30/35 (86%) patients saw Hematology at any point from conception to delivery, with 25 of these visits being after the initial prenatal visit with OBGYN or MFM. 2 of the remaining 5 patients had scheduled visits that were cancelled. 30/35 (86%) of patients saw Genetics at any time pre-delivery or had a documented reason for not referring. 34/35 (97%) had a documented discussion of partner SCD testing by any provider. 2/35 (6%) underwent amniocentesis. 3 patients were seen or referred to REI at any point during or before pregnancy, out of 16 with a history of pregnancy loss (19%).
Conclusions
In this specialized tertiary SCD program, utilization of SMFM-recommended multidisciplinary services during pregnancy, including MFM, Hematology, Genetics, and Social Work, was high. However, referrals for complication-specific subspecialty care were less consistent. Specifically, REI was underutilized despite elevated pregnancy loss risk. This identified modifiable gaps in guideline-concordant care. Although limited by the single-center design and small sample size, this study provides a real-world framework for developing standardized multidisciplinary referral pathways in guiding future quality improvement efforts in prenatal SCD care. Future directions include expanding beyond a single center, increasing the variety of SCD-related complications captured to rigorously evaluate complication-specific referrals, and evaluate barriers to fertility counseling including cost.
DISCLOSURES
Kira Li Nagoshi: No relevant conflicts of interest to declare.